We found that co-treatment with sorafenib blocked the enrichment of CRC cells containing mutations of either EGFR extracellular domain or KRAS induced by cetuximab (Fig. 2G, H), indicating that sorafenib could prolong the response to targeted therapy in other types of EGFR-addicted tumors. This evidence concerns the gene KRAS and colorectal carcinoma.